Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM)

Paul G. Richardson, MD, Andrew Spencer, MD, Paul Cannell, MBBS, FRCPA, FRACP, Simon J. Harrison, MBBS MRCP (uk) MRCPath (uk) PhD, Laurence Catley, MBBS, FRCPA, FRACP, Craig Underhill, MBBS, FRACP, Todd M. Zimmerman, MD, Craig C. Hofmeister, MD, Andrzej J Jakubowiak, MD, PhD, Jacob P. Laubach, MD, Michael A. Palladino, PhD, Angie M. Longenecker, RN, BSN, Ana Lay, Sandra Wear, RN, G. Kenneth Lloyd, PhD, Alison L. Hannah, MD, Steve Reich, MD, Matthew A. Spear, MD, Kenneth C. Anderson, MD

Blood (2011) 118 (21): 302.

https://doi.org/10.1182/blood.V118.21.302.302

Published: 2011

Journal Articles

A Novel Acanthoic Acid Analog NPI-1342 Blocks IκB Kinase-α and Trigger In Vitro and In Vivo cytotoxicity in Multiple Myeloma Cells

Dharminder Chauhan, PhD, Ajita V. Singh, Arghya Ray, Ph.D, Teru Hideshima, MD, PhD, Paul G. Richardson, MD, Michael A. Palladino, PhD, Kenneth C. Anderson, MD

Blood (2011) 118 (21): 1841.

https://doi.org/10.1182/blood.V118.21.1841.1841

Published: 2011

Journal Articles

Inhibition of the RKIP and PTEN-Transcription Repressor Snail in B-NHL by the Proteasome Inhibitor NPI-0052: Roles of RKIP and PTEN Induction in the Reversal of Resistance to TRAIL Apoptosis.

Stavroula Baritaki, Kam Yeung, Ph.D., Katherine Wu, Haiming Chen, MD, PhD, James R. Berenson, MD, Michael A. Palladino, PhD, Benjamin Bonavida, PhD

Blood (2009) 114 (22): 3938.

https://doi.org/10.1182/blood.V114.22.3938.3938

Published: 2009

Journal Articles

Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052 in Patients with Relapsed and Relapsed/Refractory Multiple Myeloma (MM).

Paul Richardson, M.D, Craig Hofmeister, MD, Andrzej Jakubowiak, MD, PhD, Todd M. Zimmerman, MD, Matthew A. Spear, MD, Michael A. Palladino, PhD, Angie M. Longenecker, RN, BSN, Susan L. Kelly, MD, Saskia Neuteboom, PhD, Gillian F Cropp, MSc, G. Kenneth Lloyd, PhD, Alison L. Hannah, MD, Kenneth C. Anderson, MD

Blood (2009) 114 (22): 431.

https://doi.org/10.1182/blood.V114.22.431.431

Published: 2009

Journal Articles

NPI-2358, a Novel Vascular Disrupting Agent Blocks Growth and Angiogenesis in Multiple Myeloma Cells.

Dharminder Chauhan, Ph.D, Ajita V. Singh, Madhavi Bandi, Noopur Raje, M.D., Robert L Schlossman, M.D., G. Kenneth Lloyd, PhD, Paul Richardson, Michael A. Palladino, PhD, Kenneth C. Anderson, MD

Blood (2009) 114 (22): 3842.

https://doi.org/10.1182/blood.V114.22.3842.3842

Published: 2009

Journal Articles

Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052.

Andrew Spencer, Michael Millward, MD, Paul Mainwaring, MD, Simon Harrison, MD, Laurence Catley, MBBS, FRCPA, FRACP, Amanda Townsend, MD, Shawgi Sukumaran, MD, Angie M. Longenecker, RN, BSN, Michael A. Palladino, PhD, G. Kenneth Lloyd, PhD, Saskia Neuteboom, PhD, Peeter Padrik, MD, Matthew A. Spear, MD, Timothy Price, MD

Blood (2009) 114 (22): 2693.

https://doi.org/10.1182/blood.V114.22.2693.2693

Published: 2009

Journal Articles

Phase 1 Clinical Trial of NPI-0052, a Novel Proteasome Inhibitor in Patients with Multiple Myeloma

Paul Richardson, MD, Craig C. Hofmeister, MD, Todd M. Zimmerman, MD, Asher Alban Chanan-Khan, MD, Matthew A. Spear, MD, Michael A. Palladino, PhD, Angie M. Longenecker, RN, BSN, Gillian Cropp, MS, G. Kenneth Lloyd, PhD, Sandra Wear, Alison L. Hannah, MD, Kenneth C Anderson, MD

Blood (2008) 112 (11): 2770.

https://doi.org/10.1182/blood.V112.11.2770.2770

Published: 2008

Journal Articles

Combination of a Novel Proteasome Inhibitor NPI-0052 and Lenalidomide Trigger in Vivo Synergistic Cytotoxicity in Multiple Myeloma

Dharminder Chauhan, PhD, Ajita V. Singh, Mohan Brahmandam, Giada Bianchi, Klaus Podar, Teru Hideshima, Nikhil Munshi, Paul Richardson, Michael A. Palladino, PhD, Kenneth C. Anderson

Blood (2008) 112 (11): 3662.

https://doi.org/10.1182/blood.V112.11.3662.3662

Published: 2008

Journal Articles

Pharmacodynamic and Efficacy Studies of a Novel Proteasome Inhibitor NPI-0052 in Human Plasmacytoma Xenograft Mouse Model

Ajita V. Singh, G. Kenneth Lloyd, Michael A. Palladino, PhD, Dharminder Chauhan, Kenneth C. Anderson

Blood (2008) 112 (11): 3665.

https://doi.org/10.1182/blood.V112.11.3665.3665

Published: 2008

Journal Articles

Clinical Trial of NPI-0052 (2nd generation proteasome inhibitor) in Patients Having Advanced Malignancies with Expanded RP2D Cohorts in Lymphoma and CLL

Timothy Price, MD, Peeter Padrik, MD, Amanda Townsend, MD, Paul Mainwaring, MD, Lawrence Catley, MD, Angie M. Longenecker, RN, BSN, Gillian Cropp, MS, Michael A. Palladino, PhD, G. Kenneth Lloyd, PhD, Matthew A. Spear, MD, Michael Millward, MD

Blood (2008) 112 (11): 4934.

https://doi.org/10.1182/blood.V112.11.4934.4934

Published: 2008

Journal Articles

Synergy in Apoptosis Is Achieved in B-NHL by the Combination of Rituximab and the Novel Proteasome Inhibitor NPI-0052: Pivotal Role of Induction of the Immune Surveillance Cancer Gene Product RKIP

Mario I. Vega, PhD, Melisa Martinez- Paniagua, Sara Huerta-Yepez, PhD., Eriko Suzuki, Kazuo Umezawa, Kam Yeung, Ph.D., Massimo Libra, Stavroula Baritaki, Michael A. Palladino, PhD, Benjamin Bonavida, PhD

Blood (2008) 112 (11): 4973.

https://doi.org/10.1182/blood.V112.11.4973.4973

Published: 2008

Journal Articles

First-in-Human Phase 1 Dose Escalation Study of NPI-0052, a Novel Proteasome Inhibitor, in Patients with Lymphoma and Solid Tumor

Paul A. Hamlin, MD, Carol Aghajanian, M.D., David Hong, M.D., Anas Younes, M.D., Michael A. Palladino, PhD, Angie M. Longenecker, RN, BSN, Gillian Cropp, MS, G. Kenneth Lloyd, PhD, Alison L. Hannah, MD, Matthew A. Spear, MD, Razelle Kurzrock, MD

Blood (2008) 112 (11): 4939.

https://doi.org/10.1182/blood.V112.11.4939.4939

Published: 2008

NARROW

Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM)

A Novel Acanthoic Acid Analog NPI-1342 Blocks IκB Kinase-α and Trigger In Vitro and In Vivo cytotoxicity in Multiple Myeloma Cells

Inhibition of the RKIP and PTEN-Transcription Repressor Snail in B-NHL by the Proteasome Inhibitor NPI-0052: Roles of RKIP and PTEN Induction in the Reversal of Resistance to TRAIL Apoptosis.

Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052 in Patients with Relapsed and Relapsed/Refractory Multiple Myeloma (MM).

NPI-2358, a Novel Vascular Disrupting Agent Blocks Growth and Angiogenesis in Multiple Myeloma Cells.

Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052.

Phase 1 Clinical Trial of NPI-0052, a Novel Proteasome Inhibitor in Patients with Multiple Myeloma

Combination of a Novel Proteasome Inhibitor NPI-0052 and Lenalidomide Trigger in Vivo Synergistic Cytotoxicity in Multiple Myeloma

Pharmacodynamic and Efficacy Studies of a Novel Proteasome Inhibitor NPI-0052 in Human Plasmacytoma Xenograft Mouse Model

Clinical Trial of NPI-0052 (2nd generation proteasome inhibitor) in Patients Having Advanced Malignancies with Expanded RP2D Cohorts in Lymphoma and CLL

Synergy in Apoptosis Is Achieved in B-NHL by the Combination of Rituximab and the Novel Proteasome Inhibitor NPI-0052: Pivotal Role of Induction of the Immune Surveillance Cancer Gene Product RKIP

First-in-Human Phase 1 Dose Escalation Study of NPI-0052, a Novel Proteasome Inhibitor, in Patients with Lymphoma and Solid Tumor

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only